期刊文献+

2014~2019年我院ICU感染病原菌分布及耐药性分析 被引量:3

Analysis of the Distribution and Drug Resistance of Pathogenic Bacteria in the ICU of Our Hospital from 2014 to 2019
下载PDF
导出
摘要 目的分析我院ICU患者感染病原菌的分布及耐药性,为临床合理选择抗菌药物提供依据。方法回顾我院ICU 2014年1月~2019年12月送检各类型标本所分离的病原菌,分析其耐药性。结果 6年共分离出病原菌3407株,其中革兰阴性杆菌2511株(73.70%),以鲍曼不动杆菌、铜绿假单胞菌、肺炎克雷伯菌、大肠埃希氏菌为主;革兰阳性球菌896株(26.30%),以屎肠球菌、金黄色葡萄球菌、粪肠球菌、人葡萄球菌为主。鲍曼不动杆菌对所检测的抗菌药物均保持较高耐药率(72.89%~79.56%),铜绿假单胞菌对氨基糖苷类(阿米卡星,庆大霉素)抗菌药物保持较高的敏感性(8.15%~15.31%),其次为哌拉西林/他唑巴坦(24.63%)和头孢他啶(30.95%)。肺炎克雷伯菌对各种抗菌药物的耐药率整体高于大肠埃希氏菌,其中大肠埃希氏菌对亚胺培南和美罗培南耐药率分别为8.67%和10.00%,而对左旋氧氟沙星和环丙沙星耐药率分别为67.33%和66.67%;肺炎克雷伯菌除了对阿米卡星具有稍低的耐药性(38.15%),对其他各类抗菌药物的耐药率波动在40.76%~63.45%。葡萄球菌属细菌对红霉素、青霉素具有较高的耐药率,波动在73.82%~82.09%,对万古霉素和利奈唑胺耐药率为0。屎肠球菌和粪肠球菌对万古霉素和利奈唑胺具有较高的敏感性,耐药率波动在0.62%~13.85%。结论我院ICU感染病原菌主要为革兰阴性杆菌,且耐药情况严重,以鲍曼不动杆菌耐药显著。应加强对ICU病原菌的耐药性监测,指导临床合理选用抗菌药物。 Objective To analyze the distribution and drug resistance of infectious pathogens in ICU patients in our hospital,and provide a basis for clinically reasonable selection of antimicrobial drugs.Methods To review the pathogenic bacteria isolated from various types of specimens sent to the ICU in our hospital from January 2014 to December 2019,and analyze their drug resistance.Results A total of 3407 strains of pathogenic bacteria were isolated in 6 years,among which 2511 strains(73.70%)of gram-negative bacilli,mainly Acinetobacter baumannii,Pseudomonas aeruginosa,Klebsiella pneumoniae,and Escherichia coli;Gram 896 strains(26.30%)of positive cocci were mainly Enterococcus faecium,Staphylococcus aureus,Enterococcus faecalis,and Staphylococcus human.Acinetobacter baumannii maintained a high resistance rate(72.89%-79.56%)to the tested antibacterial drugs.Pseudomonas aeruginosa maintained relatively high resistance to aminoglycoside(amikacin,gentamicin)antibacterial drugs.High sensitivity(8.15%-15.31%),followed by piperacillin/tazobactam(24.63%)and ceftazidime(30.95%).The resistance rate of Klebsiella pneumoniae to various antibacterial drugs is higher than that of Escherichia coli.The resistance rates of Escherichia coli to imipenem and meropenem are 8.67%and 10.00%,respectively.The resistance rates of ofloxacin and ciprofloxacin are 67.33%and 66.67%,respectively;Klebsiella pneumoniae has a slightly lower resistance to amikacin(38.15%),and is resistant to other types of antibacterial drugs.The resistance rate fluctuated from 40.76%to 63.45%.Staphylococcus bacteria have a high resistance rate to erythromycin and penicillin,fluctuating from 73.82%to 82.09%,and the resistance rate to vancomycin and linezolid is 0.Enterococcus faecium and Enterococcus faecalis are highly sensitive to vancomycin and linezolid,and the resistance rate fluctuates from 0.62%to 13.85%.Conclusion The pathogens of the ICU infection in our hospital are mainly Gram-negative bacilli,and the drug resistance is serious,Acinetobacter baumannii has significant drug resistance.The drug resistance monitoring of pathogens in ICU should be strengthened to guide the rational selection of antibacterial drugs in clinic.
作者 王春梅 闫琳琳 农金轻 谷依林 胡守奎 WANG Chun-mei;YAN Lin-lin;NONG Jin-qing;GU Yi-lin;HU Shou-kui(Department of Laboratory Medicine,Peking University Shougang Hospital,Beijing 100144,China)
出处 《医学信息》 2020年第22期134-137,共4页 Journal of Medical Information
关键词 ICU 病原菌 耐药性 多重耐药 ICU Pathogenic bacteria Drug resistance Multiple drug resistance
  • 相关文献

参考文献10

二级参考文献110

  • 1圣艳,全金花.海口1家三甲医院ICU病原菌的分布调查及耐药性分析[J].临床检验杂志(电子版),2013,2(1):291-294. 被引量:1
  • 2卓超,黄文祥,盛家琦,蒋玉富,陈庆宪.重症监护病房革兰阴性杆菌连续六年耐药性监测研究[J].中华检验医学杂志,2004,27(11):752-756. 被引量:70
  • 3胡必杰,魏丽,张秀珍,唐英春,倪语星,黎毅敏,郭纪全,胡云建,张扣兴,杨莉.医院获得性肺炎发病时间对病原构成影响的回顾性队列研究[J].中华结核和呼吸杂志,2005,28(2):112-116. 被引量:48
  • 4刘又宁,陈民钧,赵铁梅,王辉,王睿,刘庆锋,蔡柏蔷,曹彬,孙铁英,胡云建,修清玉,周新,丁星,杨岚,卓建生,唐英春,张扣兴,梁德荣,吕晓菊,李胜歧,刘勇,俞云松,魏泽庆,应可净,赵峰,陈萍,侯晓娜.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8. 被引量:784
  • 5杨秀捷,张晨,齐文升,蓝海涛,王硕,杨忆熙,赵昕,叶锡鲁,马荣.重症加强治疗病房鲍曼不动杆菌耐药性分析及其与中医证候的关系[J].中国中西医结合急救杂志,2007,14(4):222-224. 被引量:22
  • 6Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii:emergence of a successful pathogen. Clin Microbiol Rev, 2008,21 : 538-582.
  • 7Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimierobial. Antimicrob Agents Chemother,2006 ,50 :3479-3484.
  • 8Guner R, Hasanoglu I, Keske S, et al. Outcome in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection, 2011,39: 515-518.
  • 9Hoban D J, Bouchillon SK, Dowzicky MJ. Antimicrobial susceptibility of extended-spectrum-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn Microbiol Infect Dis ,2007,57:423-428.
  • 10Metan G, Alp E, Yildiz O, et al. Clinical experience with tigecycline in the treatment of earbapenem-resistant Aeinetobacter infections. J Chemother,2010,22 : 110-114.

共引文献459

同被引文献40

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部